-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Livzon Pharmaceutical (01513.HK) issued an announcement. Recently, the company's holding subsidiary Shanghai Lizhu Pharmaceutical Co., Ltd. (Shanghai Lizhu) received the “Drug Supplement Application Approval Notice” (certificate number: 2026B06648) approved and issued by the State Drug Administration, and 11.25mg (3-month dosage form) of injectable leuprorelin acetate microspheres produced by Shanghai Lizhu was approved for listing.

Zhitongcaijing·09/29/2026 10:57:09
Listen to the news
Zhitong Finance App News, Livzon Pharmaceutical (01513.HK) issued an announcement. Recently, the company's holding subsidiary Shanghai Lizhu Pharmaceutical Co., Ltd. (Shanghai Lizhu) received the “Drug Supplement Application Approval Notice” (certificate number: 2026B06648) approved and issued by the State Drug Administration, and 11.25mg (3-month dosage form) of injectable leuprorelin acetate microspheres produced by Shanghai Lizhu was approved for listing.